| ADMIN | STUDY | CLOSE DATE |
Intergroup Study |
OPEN | COOPGRP | COUNT |
|---|---|---|---|---|---|---|
| BREAST | S2206-Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva | Y | ALLIANCE | 50 | ||
| ECOG-ACRIN | 71 | |||||
| NRG | 41 | |||||
| SWOG | 205 | |||||
| sum | 367 | |||||
| S2212-Breast, TNBC, Neoadj Chemo + Pembro | Y | ALLIANCE | 242 | |||
| ECOG-ACRIN | 235 | |||||
| NRG | 151 | |||||
| SWOG | 753 | |||||
| sum | 1381 | |||||
| CCD | S1703-Met Breast, STM-monitoring v Usual Care | Y | ALLIANCE | 22 | ||
| ECOG-ACRIN | 32 | |||||
| NRG | 24 | |||||
| SWOG | 379 | |||||
| sum | 457 | |||||
| S2417CD-Colrec Surv, Follow-up w/ CTAC site | Y | ALLIANCE | 14 | |||
| ECOG-ACRIN | 2 | |||||
| NRG | 1 | |||||
| SWOG | 53 | |||||
| sum | 70 | |||||
| ERLYTX | EAY191-S3-ComboMATCH: Adv Solid Tumors, Pac+Ipatasertib | 18-DEC-25 | T | ALLIANCE | 6 | |
| ECOG-ACRIN | 9 | |||||
| NRG | 10 | |||||
| SWOG | 8 | |||||
| sum | 33 | |||||
| S2012-Extrapulm NEC, Stg IV, Combo Chemo +/- Atezo | Y | ALLIANCE | 27 | |||
| ECOG-ACRIN | 15 | |||||
| NRG | 12 | |||||
| SWOG | 100 | |||||
| sum | 154 | |||||
| SN2426-cSCC, IC Met/Inop, Amivantamab v Cetuximab | Y | SWOG | 5 | |||
| sum | 5 | |||||
| GI | S1922-Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect | Y | ALLIANCE | 12 | ||
| ECOG-ACRIN | 3 | |||||
| NRG | 3 | |||||
| SWOG | 28 | |||||
| sum | 46 | |||||
| S2104-Panc,Resect High-risk,Postop Adj Chemo vs Obs | Y | ALLIANCE | 12 | |||
| ECOG-ACRIN | 13 | |||||
| NRG | 8 | |||||
| SWOG | 62 | |||||
| sum | 95 | |||||
| S2303-Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo | Y | ALLIANCE | 31 | |||
| ECOG-ACRIN | 8 | |||||
| NRG | 6 | |||||
| SWOG | 50 | |||||
| sum | 95 | |||||
| GU | S1802-Pros, Stg IV, SST ± Surg/RT to Primary Tum | Y | ALLIANCE | 124 | ||
| ECOG-ACRIN | 109 | |||||
| NRG | 127 | |||||
| SWOG | 659 | |||||
| sum | 1019 | |||||
| S1931-RENAL, Stg IV, IO + Nephrectomy. vs IO Only | Y | ALLIANCE | 9 | |||
| ECOG-ACRIN | 17 | |||||
| NRG | 16 | |||||
| SWOG | 108 | |||||
| sum | 150 | |||||
| S1937-Blad, Mets, Eribulin + Gem vs SOC | 13-MAR-26 | T | ALLIANCE | 7 | ||
| ECOG-ACRIN | 22 | |||||
| NRG | 3 | |||||
| SWOG | 100 | |||||
| sum | 132 | |||||
| S2200-pRCC, Adv, Cabo ± Atezo | 16-JAN-26 | N | ALLIANCE | 2 | ||
| ECOG-ACRIN | 6 | |||||
| NRG | 4 | |||||
| SWOG | 24 | |||||
| sum | 36 | |||||
| S2210-Pros, High Risk, BRCA, Neoadj Carbo | Y | SWOG | 6 | |||
| sum | 6 | |||||
| S2427-Blad, MIBC, RT + Pembrolizumab | Y | ALLIANCE | 4 | |||
| ECOG-ACRIN | 2 | |||||
| SWOG | 6 | |||||
| sum | 12 | |||||
| LEUK | MM1OA-S03-AML, Newly Dx, Ven+ASTX727 vs Ven+ASTX727+Ena | Y | ECOG-ACRIN | 3 | ||
| NRG | 2 | |||||
| SWOG | 4 | |||||
| sum | 9 | |||||
| MM1YA-S01-AML, High Risk, Age <60, 7+3 vs experimental | Y | ALLIANCE | 12 | |||
| ECOG-ACRIN | 15 | |||||
| NRG | 2 | |||||
| SWOG | 41 | |||||
| sum | 70 | |||||
| MYELOMATCH-MSRP for the NCI myeloMATCH Clinical Trials | Y | ALLIANCE | 261 | |||
| CCTG | 68 | |||||
| ECOG-ACRIN | 239 | |||||
| NRG | 46 | |||||
| SWOG | 470 | |||||
| sum | 1084 | |||||
| S1905-T-ALL/T-LBL, Rel/Ref, OBI-3424 | 15-FEB-26 | N | ALLIANCE | 2 | ||
| COG | 1 | |||||
| ECOG-ACRIN | 2 | |||||
| SWOG | 19 | |||||
| sum | 24 | |||||
| S1925-CLL/SLL, Newly Dx HR, Early vs Delayed V+O | Y | ALLIANCE | 55 | |||
| CCTG | 14 | |||||
| ECOG-ACRIN | 19 | |||||
| NRG | 6 | |||||
| SWOG | 94 | |||||
| sum | 188 | |||||
| LUNG | LUNGMAP-NSCLC, Adv, Master | Y | ALLIANCE | 937 | ||
| ECOG-ACRIN | 404 | |||||
| NRG | 543 | |||||
| SWOG | 2109 | |||||
| sum | 3993 | |||||
| S1800E-Non-Match: Docetaxel + Ramu +/- Cemiplimab | Y | ALLIANCE | 18 | |||
| ECOG-ACRIN | 11 | |||||
| NRG | 9 | |||||
| SWOG | 54 | |||||
| sum | 92 | |||||
| S1827-SCLC, MRI Surveillance +/- PCI | 15-DEC-25 | N | ALLIANCE | 29 | ||
| CCTG | 39 | |||||
| ECOG-ACRIN | 11 | |||||
| NRG | 89 | |||||
| SWOG | 136 | |||||
| sum | 304 | |||||
| S1900G-EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu | Y | ALLIANCE | 3 | |||
| ECOG-ACRIN | 1 | |||||
| NRG | 3 | |||||
| SWOG | 18 | |||||
| sum | 25 | |||||
| S1900J-MET Amplification: Amivantamab Hyaluronidase | Y | ALLIANCE | 1 | |||
| SWOG | 3 | |||||
| sum | 4 | |||||
| S1900K-MET Exon 14: Tepotinib +/- Ramucirumab | Y | ALLIANCE | 4 | |||
| ECOG-ACRIN | 10 | |||||
| SWOG | 11 | |||||
| sum | 25 | |||||
| S1933-NSCLC, Stg II-III, RT + Atezo | 15-FEB-26 | N | ALLIANCE | 5 | ||
| NRG | 2 | |||||
| SWOG | 41 | |||||
| sum | 48 | |||||
| S2409-ESCLC, Durvalumab +/- Biomarker Directed Tx | Y | ECOG-ACRIN | 3 | |||
| SWOG | 2 | |||||
| sum | 5 | |||||
| S2414-NSCLC, Stg II-IIIB, Durva vs Surveillance | Y | ECOG-ACRIN | 1 | |||
| SWOG | 8 | |||||
| sum | 9 | |||||
| LYMPH | S2114-NHL, Rel/Ref, CD19 CAR-T +/- Consolidation | Y | ALLIANCE | 61 | ||
| ECOG-ACRIN | 19 | |||||
| NRG | 11 | |||||
| SWOG | 127 | |||||
| sum | 218 | |||||
| S2207-LBCL, Transplant Inelig, Targeted Tx + Tafa | 06-MAR-26 | T | ALLIANCE | 7 | ||
| NRG | 5 | |||||
| SWOG | 27 | |||||
| sum | 39 | |||||
| S2308-FL, LTB, Mosunetuzumab vs Rituximab | Y | ALLIANCE | 65 | |||
| ECOG-ACRIN | 45 | |||||
| NRG | 22 | |||||
| SWOG | 194 | |||||
| sum | 326 | |||||
| MMYEL | S1803-MM, Maintenance, Len vs Len/Dara | Y | ALLIANCE | 226 | ||
| CCTG | 21 | |||||
| ECOG-ACRIN | 188 | |||||
| NRG | 117 | |||||
| SWOG | 786 | |||||
| sum | 1338 | |||||
| S2005-WM, Prev. Untreated, I/R or Z v V/R | Y | ALLIANCE | 4 | |||
| ECOG-ACRIN | 17 | |||||
| NRG | 1 | |||||
| SWOG | 5 | |||||
| sum | 27 | |||||
| S2209-MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D | Y | ALLIANCE | 16 | |||
| ECOG-ACRIN | 10 | |||||
| NRG | 5 | |||||
| SWOG | 98 | |||||
| sum | 129 | |||||
| S2213-AL Amyloidosis, Newly Dx, Dara-VCD v ASCT | Y | ALLIANCE | 11 | |||
| ECOG-ACRIN | 6 | |||||
| NRG | 2 | |||||
| SWOG | 22 | |||||
| sum | 41 | |||||
| MULT | S2101-Melan or HNSCC, Adv, Cabo + Nivo | Y | ALLIANCE | 21 | ||
| ECOG-ACRIN | 13 | |||||
| NRG | 11 | |||||
| SWOG | 49 | |||||
| sum | 94 | |||||
| PEOLC | S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol | Y | ECOG-ACRIN | 45 | ||
| SWOG | 274 | |||||
| S1501 | Y | ALLIANCE | 40 | |||
| NRG | 30 | |||||
| sum | 389 | |||||
| S2408-Panc Fistula Prevention, Lanreotide | 16-MAR-26 | T | ALLIANCE | 5 | ||
| ECOG-ACRIN | 8 | |||||
| NRG | 2 | |||||
| SWOG | 48 | |||||
| sum | 63 | |||||
| SXQOL | S2013-I-CHECKIT: ICI toxicity risk prediction study | Y | ALLIANCE | 383 | ||
| ECOG-ACRIN | 135 | |||||
| NRG | 303 | |||||
| SWOG | 1672 | |||||
| sum | 2493 | |||||
| S2205-ICE COMPRESS: Reduction of CIPN from Taxanes | Y | ALLIANCE | 88 | |||
| ECOG-ACRIN | 14 | |||||
| NRG | 148 | |||||
| SWOG | 354 | |||||
| sum | 604 | |||||